Evidence map›Paper›PMID 22468704›Full record

ArticleRadiation research2012

Development and licensure of medical countermeasures to treat lung damage resulting from a radiological or nuclear incident.

Andrea L DiCarlo, Isabel L Jackson, Jui R Shah, Christine W Czarniecki, Bert W Maidment, Jacqueline P Williams

Open access · bronzeAbstract read
In one paragraph

Article in Radiation research, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 25 papers.

0numbers the graph read from it
0cells of the map it votes in
25citing papers in PubMed
2.5field-weighted citation impact, top 11% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

25 citing papers in PubMed, 31 citations in OpenAlex.

  1. Article
  2. Review
  3. Article
  4. Involvement of eNAMPT/TLR4 signaling in murine radiation pneumonitis: protection by eNAMPT neutralization.Translational research : the journal of laboratory and clinical medicine · 2022
    Article
  5. Article
  6. Review
  7. Article
  8. Article
  9. Article
  10. Article
  11. Article
  12. Article
  13. Article
  14. Review
  15. Review
  16. A Lipidomic and Metabolomic Serum Signature from Nonhuman Primates Exposed to Ionizing Radiation.Metabolomics : Official journal of the Metabolomic Society · 2016
    Article
  17. Article
  18. Review
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 4 institutions in 1 country.

Andrea L DiCarloDivision of Allergy, Immunology and Transplantation, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, Maryland 20892, USA. cohena@niaid.nih.gov
Isabel L Jackson
Jui R Shah
Christine W Czarniecki
Bert W Maidment
Jacqueline P Williams
National Institute of Allergy and Infectious Diseases · USNational Institutes of Health · USDuke Medical Center · USUniversity of Rochester Medical Center · US

Funding

Intramural NIH HHS Z99 AI999999
6 · The paper itself

Abstract

Due to the ever-present threat of a radiological or nuclear accident or attack, the National Institute of Allergy and Infectious Diseases, Radiation Medical Countermeasures Program was initiated in 2004. Since that time, the Program has funded research to establish small and large animal models for radiation damage, as well as the development of approaches to mitigate/treat normal tissue damage following radiation exposure. Because some of these exposures may be high-dose, and yet heterogeneous, the expectation is that some victims will survive initial acute radiation syndromes (e.g. hematopoietic and gastrointestinal), but then suffer from potentially lethal lung complications. For this reason, efforts have concentrated on the development of animal models of lung irradiation damage that mimic expected exposure scenarios, as well as drugs to treat radiation-induced late lung sequelae including pneumonitis and fibrosis. Approaches targeting several pathways are under study, with the eventual goal of licensure by the United States Food and Drug Administration for government stockpiling. This Commentary outlines the status of countermeasure development in this area and provides information on the specifics of licensure requirements, as well as guidance and a discussion of challenges involved in developing and licensing drugs and treatments specific to a radiation lung damage indication.

Indexed as

Nuclear WarfareRadioactive Hazard ReleaseAcute Radiation SyndromeAnimal ExperimentationAnimalsBiomarkersHumansLicensureLungLung DiseasesModels, AnimalNational Institute of Allergy and Infectious Diseases (U.S.)Pulmonary FibrosisRadiation Injuries, ExperimentalRadiation PneumonitisRadiation-Protective AgentsBiomarkersRadiation-Protective AgentsRadioactive Fallout

Identifiers

PMID22468704
PMCPMC8384257
OpenAlexW2103009727

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.